20:28 , Mar 11, 2019 |  BC Extra  |  Clinical News

Axovant reports first clinical gene therapy data

After rebooting to focus exclusively on gene therapies, Axovant gained $0.21 (14%) to $1.69 on Monday after reporting its first data from its retooled pipeline. The lowest dose of its Parkinson's disease therapy, AXO-Lenti-PD, was...
19:29 , Dec 21, 2018 |  BC Week In Review  |  Company News

Axovant gets rights to gene therapies from UMass medical school

The University of Massachusetts Medical School (Worcester, Mass.) granted Axovant exclusive, worldwide rights to develop and commercialize two gene therapies to treat GM1 and GM2 gangliosidoses. The school received $10 million up front and is...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

MabVax, Telik deal

The cancer companies will merge in a stock deal to create a publicly traded company named MabVax Therapeutics Holdings Inc. Telik shareholders will own 15% of the combined company, and MabVax shareholders will own the...
07:00 , Mar 18, 2013 |  BioCentury  |  Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
08:00 , Jan 28, 2013 |  BioCentury  |  Tools & Techniques

BioMarin's brainy buy

The winding down of a 2011 development deal between Zacharon Inc. and Pfizer Inc. gave erstwhile suitor BioMarin Pharmaceutical Inc. a new opening to buy the company. The acquisition is also the latest in a...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Clinical News

Sarcoma vaccine: Phase II started

MabVax began a double-blind, U.S. Phase II trial to compare its subcutaneous sarcoma vaccine with adjuvant compared to adjuvant alone in 126 patients. MabVax licensed the vaccine from Memorial Sloan-Kettering Cancer Center (New York, N.Y.)...
08:00 , Jan 4, 2010 |  BioCentury  |  Emerging Company Profile

MabVax: The Bs have it

MabVax Therapeutics Inc. hopes that by focusing on the B cell immune response and going after multiple antigens with its polyvalent therapeutic cancer vaccines, it can improve patient survival where other cancer vaccines have failed....
07:00 , Jul 9, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer; prostate cancer Globohexaosylceramide (globo-H); ganglioside GM2 (GM2); Thomsen-Friedenreich antigen (TF); Tn antigen (Tn); sialosyl-Tn antigen (sTn) In vitro studies suggest that a pentavalent...
07:00 , May 29, 2006 |  BioCentury  |  Product Development

Late-stage cancer vaccines

Late-stage cancer vaccines Company Product Description Indication Status Trial details Accentia BiovaxID Vaccine containing tumor-specific idiotype protein from the patient's lymphoma cells and conjugated to Keyhole-Limpet- Hemocyanin (KLH), an adjuvant to stimulate an immune response...
08:00 , Nov 15, 2004 |  BioCentury  |  Strategy

Melanoma pipeline

Melanoma pipeline Compound Description Status Company DTIC-Dome dacarbazine Imidazole carboxamide derivative Mkt Bayer Intron A Interferon alpha-2b Mkt Schering-Plough Proleukin aldesleukin Recombinant IL-2 Mkt Chiron Canvaxin Allogeneic whole cell vaccine expressing 38 tumor-associated antigens Ph...